BMS de­tails con­fir­ma­to­ry tri­al win for KRAS in­hibitor Kraza­ti

Bris­tol My­ers Squibb said its KRAS can­cer drug Kraza­ti met the pri­ma­ry end­point in a Phase 3 con­fir­ma­to­ry tri­al in pa­tients with non-small cell lung …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.